Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2015

01-04-2015 | Editorial

Bacterial Pathogen Helicobacter pylori: A Bad AKT or Inhibits p53 Protein Activity

Author: Alexander I. Zaika

Published in: Digestive Diseases and Sciences | Issue 4/2015

Login to get access

Excerpt

Gastric colonization by Helicobacter pylori is the most prominent known risk factor for gastric cancer. A complex interplay between host and bacterial factors underlies tumorigenic alterations induced by the bacteria, of which many aspects are not well understood. Recent studies have provided new data regarding regulation of the host protein p53 by H. pylori. The interest in p53 originates from its key role in tumor suppression, paraphrased in the scientific literature as “the guardian of the genome.” Indeed, inactivation of p53 is strongly associated with an increased susceptibility to numerous tumors in animals and humans, with p53 commonly inactivated during gastric tumorigenesis. …
Literature
1.
Wei J, Nagy TA, Vilgelm A, et al. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology. 2010;139:1333–1343.
2.
Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci USA. 2011;108:9238–9243.CrossRefPubMedCentralPubMed
3.
Tsugawa H, Suzuki H, Saya H, et al. Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host Microbe. 2012;12:764–777.CrossRefPubMed
4.
Umehara S, Higashi H, Ohnishi N, Asaka M, Hatakeyama M. Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma. Oncogene. 2003;22:8337–8342.CrossRefPubMed
5.
6.
Xu Shu, Zhen Yang, Zhong-hua Li, et al. Helicobacter pylori infection activates the Akt–Mdm2–p53 signaling pathway in gastric epithelial cells. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-014-3470-2.
7.
Sasaki T, Kuniyasu H, Luo Y, et al. Increased phosphorylation of AKT in high-risk gastric mucosa. Anticancer Res. 2013;33:3295–3300.PubMed
8.
9.
Wroblewski LE, Piazuelo MB, Chaturvedi R, et al. Helicobacter pylori targets cancer-associated apical-junctional constituents in gastroids and gastric epithelial cells. Gut. 2014. doi:10.​1136/​gutjnl-2014-307650.
Metadata
Title
Bacterial Pathogen Helicobacter pylori: A Bad AKT or Inhibits p53 Protein Activity
Author
Alexander I. Zaika
Publication date
01-04-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3511-x

Other articles of this Issue 4/2015

Digestive Diseases and Sciences 4/2015 Go to the issue

Original Article

Low-Dose Aspirin and Non-steroidal Anti-inflammatory Drugs Increase the Risk of Bleeding in Patients with Gastroduodenal Ulcer

Editorial

E-cadherin Is Important for the Maintenance of Intestinal Epithelial Homeostasis Under Basal and Inflammatory Conditions

Original Article

Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences

Original Article

Endoscopic Retrograde Cholangiography Using an Anterior Oblique-Viewing Endoscope in Patients with Altered Gastrointestinal Anatomy

Editorial

Hepatitis C Direct Antiviral Drugs and Hepatic Decompensation in Patients with Advanced Cirrhosis: Culprit or Innocent Bystander?

GRG Profiles and Perspectives

Teaching in the Office
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits